latizolil 50 mikrogrami/ml acu pilieni, šķīdums
sandoz d.d., slovenia - latanoprosts - acu pilieni, šķīdums - 50 μg/ml
maxitrol acu pilieni, suspensija
novartis baltics, sia, latvia - dexamethasonum, neomycini sulfas, polymyxini b sulfas - acu pilieni, suspensija - 1 mg/3500sv/6000 sv/ml
tobradex 3 mg/1 mg/ml acu pilieni, suspensija
novartis baltics, sia, latvia - tobramycinum, dexamethasonum - acu pilieni, suspensija - 3 mg/1 mg/ml
ciloxan 3 mg/ml acu pilieni, šķīdums
novartis baltics, sia, latvia - ciprofloksacīns - acu pilieni, šķīdums - 3 mg/ml
duotrav
novartis europharm limited - travoprostu, timololu - glaucoma, open-angle; ocular hypertension - oftalmoloģiskie līdzekļi - pieaugušiem pacientiem ar atvērta leņķa glaukoma vai acs hipertensija, kuri nepietiekami reaģē uz aktuāliem beta-blokatori vai prostaglandin analogiem samazinājums intraokulārās spiediena (iop).
maxitrol acu pilieni, suspensija
novartis pharmaceuticals uk limited, united kingdom - dexamethasonum, neomycini sulphas, polymyxini b sulfas - acu pilieni, suspensija - 1 mg/3500sv/6000 sv/ml
tears naturale acu pilieni, šķīdums
novartis pharmaceuticals uk limited, united kingdom - dextranum, hypromellosum - acu pilieni, šķīdums - 1 mg/ml + 3 mg/ml
maxitrol acu pilieni, suspensija
novartis hrvatska d.o.o, croatia - dexamethasonum, neomycini sulfas, polymyxini b sulfas - acu pilieni, suspensija - 1 mg/3500sv/6000 sv/ml
zenapax
roche registration ltd. - daclizumab - graft rejection; kidney transplantation - imūnsupresanti - zenapax ir indicēts orgānu akūtu atteikuma de novo allogenic nieru transplantācijas profilaksei un ir jālieto kopā ar imunitāti nomācošu režīms, ieskaitot cyclosporine un kortikosteroīdi pacientiem, kuriem nav imunizēti augsti.
faslodex
astrazeneca ab - fulvestrant - krūts audzējs - endokrīnās terapijas, anti-estrogēnu - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pirms vai perimenopausal sievietes, kombinējot ārstēšanu ar palbociclib būtu jāapvieno ar luteinizējošais hormona atbrīvojošo hormonu (lhrh) agonistu.